Pharmalot... Pharmalittle... Good Morning

Hello, everyone, and how are you this morning? We are bracing for a particularly busy day, because we will be moderating a panel at the big DIA show this afternoon (

look here). Wish us luck. Meanwhile, a couple of colleagues will help out and post a story or two in an effort to maintain the usual flow of items. Just the same, send us a note if you hear anything interesting. Now, though, it is time to grab that cup of stimulation and get started. Here are some tidbits. Have a great day...

Vivus And Arena: A Tale Of Dueling FDA Panel Minutes (TheStreet)

Statins Are Similarly Effective In Men And Women: Study (Reuters)

Watson Challenges Pfizer Pristiq Patent (Associated Press)

Pharma Pipeline May Be Improving (Reuters)

J&J Sold Mesh Implant After FDA Ordered Sales To End (Bloomberg News)

Affordable Care Act Saved Seniors Money On Drugs (Los Angeles Times)

Kythera Bio Hopes To Cure Double Chins (Los Angeles Daily News)

Ventrus Shares Slide As Hemorrhoid Drug Fails (Pharma Times)

Pfizer Trial Patient Sues For Canceling Test (Courthouse News)

Why Glaxo Is Still Breathing (The Indepedent)

EDITOR'S NOTE: Please check this post for updates during the day

4 Comments

Jun 26, 2012 - 8:38am
Ed:

Have a cheesesteak for us- or at least a pretzel with mustard! (ok, the first isn't 'exactly kosher' but......

Jun 26, 2012 - 7:31pm
FDA Meeting minutes mean nothing anymore. Wall Street has the last word these days. The only minutes that really mean anything to me these days are those of the hedge fund managers who you can recognize at these meeings by their satellite phones and their $1200 Oliver Peoples eyeglasses. They have issued their buy/sell ratings long before anyone at the FDA even began to think about writing up the meeting minutes.
Jun 26, 2012 - 8:17pm
This evening's story below illustrates how The Street speaks louder than any FDA meeting minutes:

http://www.cnbc.com/id/47965426